Mark Hamilton

Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma. DLBCL is treated in the first line with chemoimmunotherapy and in the second line with CAR T-cell therapy. Lymphoma therapy is curative in the first- and second-line setting but can cause substantial toxicities. We can use genomic technologies to understand 1) how the cancer responds to anti-cancer therapy including tracing changes in tumor burden using blood samples and 2) how anti-cancer therapies impact the patient's immune system. The combination of this data will allow safer and more effective anti-cancer treatments. My laboratory focuses on using human samples to understand lymphoma therapy and the interaction of lymphoma therapies with hematopoiesis. I use computational methods including cell free DNA sequencing, immune repertoire sequencing, single cell RNA sequencing, and single cell DNA sequencing to understand how tumors kinetically change over time. I use isolated peripheral blood cells to understand how anti-cancer therapies alter the immune system.